The past decade has witnessed the development of B-cell receptor (BCR) signaling inhibitors (e.g., ibrutinib) and Bcl-2 inhibitors (e.g., venetoclax) that target essential cellular dependencies of CLL. Here, BCR is linked to B-cell chronic lymphocytic leukemia.